Research study Program year 2025 Source: CMS Open Payments

Next Generation Biomarkers for Progressive Multiple Sclerosis

Research payments

$3,341,359

26 payments

Through program year 2025, $3,341,359 in research payments was reported against Next Generation Biomarkers for Progressive Multiple Sclerosis, across 26 payments, paid by Genentech, Inc..

Paid by: Genentech, Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$145,547	8
2024	Research	$805,832	12
2023	Research	$442,061	1
2022	Research	$1,160,039	2
2021	Research	$255,395	2
2020	Research	$532,484	1

Breakdown

Who paid Research payments · program years 2020–2025

Genentech, Inc. $3,341,359 26 payments

Who received the money Research payments · program years 2020–2025

Johns Hopkins Univ Ipn 20032217 Organisation paid for research $1,294,042 15 payments
Johns Hopkins Univ Organisation paid for research $1,160,039 2 payments
The Johns Hopkins University Central Lockbox Organisation paid for research $787,879 3 payments
John Hopkins University Office Of Cme Organisation paid for research $67,448 5 payments
Johns Hopkins University Organisation paid for research $31,949 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

1 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

Peter Calabresi Baltimore, MD Named on 26 payments

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.